BrightCandle
Senior Member (Voting Rights)
UK Government ME/CFS Research Spend
On 4th November 2026, Munira Wilson MP asked the government (UIN 40930) what share of UKRI and NIHR funding goes to Myalgic Encephalomyelitis. The written response by Chris McDonald MP who serves as a Minister of State in both the Department of Health & Social Care, and Department for Business...
www.meresearch.org.uk
£8.19m over 6 years. This is not necessarily biomedical research either. It is known from the Delivery Plan on ME/CFS that between April 2019 and March 2024, the UK government, through NIHR and MRC, invested around £6.5 million in research into ME/CFS. This included
- the development of an activity pacing framework for the management of chronic pain and/or fatigue in adults
- £3.2 million towards the DecodeME study into the genetic underpinning of ME/CFS
- a study investigating how autoantibodies might modify blood flow in ME/CFS
- research on the development and assessment of interventions for younger children with ME/CFS
The Crunch-ME database shows research funding for ME/CFS in UK (2016 -2026) based on disease burden (measured in disability adjusted life years) is woeful – in fact, bottom of the table in comparison with selected other chronic diseases. £5 for ME/CFS, MS £74, Rheumatoid Arthritis £76, Parkinson’s £78, Motor Neuron Disease (MND) £132 and Type I diabetes £144.
The demand for greater funding has stretched across decades and from a myriad of sources – from the 2002 Gibson Report to athlete Beth Dobbin‘s open letter to Prime Minister Andy Burnham.
The burden of research funding, of creating and maintaining researchers in the field and laying the base work for future endeavours has, in reality fallen on charities – and ME Research UK in particular.
Broadly speaking(...), since April 2020 to Oct 2026, ME Research alone has invested over £3m in research projects globally, and almost £670,000 in Phd-level research and Fellowships. Niche charity supported by individuals has funded roughly c£3.7m with modest income.